Twist Bioscience restricted shares vest; 9,724 shares slated for sale
Rhea-AI Filing Summary
Twist Bioscience (TWST) filed a Form 144 reporting a proposed sale of 9,724 common shares with an aggregate market value of $312,986.38, to be sold through Fidelity Brokerage Services LLC on 10/06/2025 on NASDAQ. The shares were acquired on 10/01/2025 through restricted stock vesting and were paid as compensation.
The filing also discloses prior sales by the same person, Paula Green, totaling 3,201 shares sold across five trades between 08/04/2025 and 10/02/2025, generating $86,859.32 in gross proceeds. The company-wide share count reported in the notice is 60,360,925 shares outstanding. The filer certifies no undisclosed material adverse information.
Positive
- Restricted stock vesting shows use of equity to compensate employees, aligning pay with company ownership
- Brokered sale via Fidelity uses an established brokerage channel, suggesting standard execution
Negative
- Planned sale of 9,724 shares (aggregate $312,986.38) will increase share supply on 10/06/2025
- Insider sold 3,201 shares for $86,859.32 in the prior three months, indicating ongoing monetization of holdings
Insights
TL;DR: An insider sale after recent restricted stock vesting increases available shares but appears routine.
The transaction shows 9,724 shares vesting on 10/01/2025 and a planned sale on 10/06/2025 through Fidelity, with an aggregate market value of $312,986.38. That links compensation vesting directly to immediate disposition of shares rather than long-term holding.
The seller previously sold 3,201 shares for $86,859.32 between 08/04/2025 and 10/02/2025, indicating repeated monetization of equity. Monitor near-term volume on NASDAQ around 10/06/2025 and any disclosed trading-plan dates to assess whether sales follow a structured plan or ad-hoc decisions.